The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 601–700 of 2,716
Hatipoğlu, B. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23197 · Cited by 39
“Antiepileptics such as phenytoin, carbamazepine, and alcohol induce hepatic enzymatic clearance of dexamethasone; to avoid possibility of inadequate DEX exposure and reliability of the test we measure dexamethasone level [30,39].”
BackgroundMethodDiagnosis of Diseases of Steroid Hormone Production, Metabolism and Action
Honour, J. W. (2009) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.v1i5.209 · Cited by 32
“establishing the degree of autonomy of this production (2-4).”
BackgroundUrinary glucocorticoid metabolites: biomarkers to classify adrenal incidentalomas?
Brossaud, J., Ducint, D., & Corcuff, J. (2016) · Clinical Endocrinology · doi:10.1111/cen.12717 · Cited by 30
Subclinical Hypercortisolism: How to Deal with It?
Chiodini, I., & Morelli, V. (2016) · Frontiers of hormone research · doi:10.1159/000443862 · Cited by 31
Pathophysiology, Evaluation, and Medical Management of Adrenal Disorders
Kutikov, A., Crispen, P. L., & Uzzo, R. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00057-8 · Cited by 34
Neto, L. V., Boguszewski, C. L., de Araújo, L. A., Bronstein, M. D., Miranda, P. A. C., Musolino, N. R. D. C., Naves, L. A., Vilar, L., Ribeiro‐Oliveira, A., & Gadelha, M. R. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000179 · Cited by 37
“These tests are indicated only for patients in whom there is a clinical suspicion of Cushing’s disease (12,36).”
BackgroundGökosmanoğlu, F., Güzel, A., Kan, E. K., & Atmaca, H. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0815 · Cited by 32
Vives, A. S., Granell, E., Gómez‐Ansón, B., Crespo, I., Pires, P., Vives‐Gilabert, Y., Valassi, E., Webb, S. M., & Resmini, E. (2017) · BioMed Research International · doi:10.1155/2017/2061935 · Cited by 36
Mondin, A., Barbot, M., Voltan, G., Tizianel, I., Vedolin, C. K., Mazzeo, P., Lazzara, M., Boscaro, M., Scaroni, C. M., & Ceccato, F. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02099-z · Cited by 31
“Endocrine society guidelines [3] recommended using either urine free cortisol (UFC), late-night salivary cortisol (LNSC) or low-dose dexamethasone suppression test (DST) to assess biochemical endogenous hypercor-tisolism.”
MethodCurrent Challenges and Future Directions in the Assessment of Glucocorticoid Status
Clarke, S. A., Eng, P. C., Comninos, A. N., Lazarus, K., Choudhury, S., Tsang, C., Meeran, K. M., Tan, T., Dhillo, W. S., & Abbara, A. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae016 · Cited by 38
Altieri, B., Secener, K., Sai, S., Fischer, C., Sbiera, S., Arampatzi, P., Kircher, S., Herterich, S., Landwehr, L., Vitcetz, S. N., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1798 · Cited by 33
Trementino, L., Michetti, G., Angeletti, A., Marcelli, G., Concettoni, C., Cardinaletti, C., Polenta, B., Boscaro, M., & Arnaldi, G. (2016) · Hormone and Metabolic Research · doi:10.1055/s-0042-101347 · Cited by 30
“The diagnosis of active CD was made on the basis of clinical features and laboratory assessments according to the consensus statement and clinical practice guidelines [12, 13].”
Siggelkow, H., Etmanski, M., Bozkurt, S., Groβ, P., Koepp, R., Brockmöller, J., & Tzvetkov, M. V. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1418 · Cited by 29
Left ventricular geometry and 24-h blood pressure profile in Cushing’s syndrome
Avenatti, E., Rebellato, A., Iannaccone, A., Battocchio, M., Dassie, F., Veglio, F., Milan, A., & Fallo, F. (2016) · Endocrine · doi:10.1007/s12020-016-0986-6 · Cited by 29
Paraneoplastic Cushing syndrome, case-series and review of the literature
Deldycke, A., Haenebalcke, C., & Taes, Y. (2017) · Acta Clinica Belgica · doi:10.1080/17843286.2017.1373927 · Cited by 31
Perge, P., Decmann, Á., Pezzani, R., Bancos, I., Fassina, A., Luconi, M., Canu, L., Tóth, M., Boscaro, M., Patócs, A., et al. (2018) · Endocrine · doi:10.1007/s12020-017-1506-z · Cited by 34
“serious morbidity and mortality associated with Cushing’s syndrome [3, 4].”
BackgroundEndocrine paraneoplastic syndromes in lung cancer
Efthymiou, C., Spyratos, D. G., & Kontakiotis, T. (2018) · HORMONES · doi:10.1007/s42000-018-0046-0 · Cited by 35
Mifepristone Treatment for Mild Autonomous Cortisol Secretion Due to Adrenal Adenomas: A Pilot Study
Belokovskaya, R., Ravikumar, A., Arumugam, D., Izadmehr, S., Goddard, G. M., Geer, E. B., & Levine, A. C. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0047 · Cited by 33
Capatina, C. A.-M., Hinojosa‐Amaya, J. M., Poiană, C., & Fleseriu, M. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1802243 · Cited by 34
Stimulated Salivary Cortisol as a Noninvasive Diagnostic Tool for Adrenal Insufficiency
Kim, Y. J., Kim, J. H., Hong, A. R., Park, K. S., Kim, S. W., Shin, C. S., & Kim, S. Y. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.707 · Cited by 32
“Late-night salivary cortisol measurements are now widely used to diagnose Cushing syndrome [14].”
MethodHair cortisol and cortisone measurements for the diagnosis of overt and mild Cushing's syndrome
Brossaud, J., Charret, L., De Angeli, D., Haissaguerre, M., Ferriere, A., Puerto, M., Gatta-Cherifi, B., Corcuff, J.-B., & Tabarin, A. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1127 · Cited by 29
Carafone, L. E., Zhang, C. D., Li, D., Lazik, N., Hamidi, O., Hurtado, M. D., Young, W. F., Thomas, M. A., Dy, B. M., Lyden, M. L., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9070741 · Cited by 35
“, facial plethora, proximal muscle weakness, supraclavicular fat pads, and wide purple-red striae) [5].”
BackgroundCastro, M. A., Ojeda, C. M., Ramírez, M. N. S., Santos, V. G. D., Corrales, E. P., & Fernández-Argüeso, M. (2022) · Endocrine · doi:10.1007/s12020-022-03120-w · Cited by 33
Treatment of Cushing Disease With Pituitary-Targeting Seliciclib
Liu, N., Ben-Shlomo, A., Carmichael, J. D., Wang, C., Swerdloff, R. S., Heaney, A. P., Barkhoudarian, G., Kelly, D. F., Noureddin, M., Lü, L., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac588 · Cited by 32
Possible, probable, and certain hypercortisolism: A continuum in the risk of comorbidity
Castro, M. A., Corrales, E. P., & Lamas, C. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.01.005 · Cited by 43
Chambre, C., McMurray, E. M., Baudry, C., Lataud, M., Guignat, L., Gaujoux, S., Lahlou, N., Guibourdenche, J., Tissier, F., Sibony, M., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0036 · Cited by 30
MURAKAMI, H., NIGAWARA, T., SAKIHARA, S., KAGEYAMA, K., YAMASHITA, M., MATSUKI, K., TANABE, J., MATSUI, J., TAMASAWA, N., & SUDA, T. (2010) · Endocrine Journal · doi:10.1507/endocrj.k09e-352 · Cited by 29
ACTH-secreting pituitary adenomas: size does not correlate with hormonal activity
Mathioudakis, N. N., Pendleton, C. A., Quiñones‐Hinojosa, A., Wand, G. S., & Salvatori, R. (2011) · Pituitary · doi:10.1007/s11102-011-0362-8 · Cited by 31
“Proximal muscle weakness is considered one of the more discriminating signs of hypercortisolism [13]; this may suggest that the lA patients have a more severe degree of hypercortisolemia.”
Cushing's Syndrome: Where and How to Find It
Debono, M., & Newell-Price, J. D. C. (2016) · Frontiers of hormone research · doi:10.1159/000443861 · Cited by 39
Self-citationFallo, F., Castellano, I., Gómez-Sánchez, C. E., Rhayem, Y., Pilon, C., Vicennati, V., Santini, D., Maffeis, V., Fassina, A., Mulatero, P., et al. (2017) · Endocrine · doi:10.1007/s12020-017-1295-4 · Cited by 29
Ceccato, F., Trementino, L., Barbot, M., Antonelli, G., Plebani, M., Denaro, L., Regazzo, D., Rea, F., Frigo, A. C., Concettoni, C., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13391 · Cited by 30
Pituitary disorders in pregnancy
Chrisoulidou, A., Boudina, M., Karavitaki, N., Bill, E., & Wass, J. A. H. (2015) · HORMONES · doi:10.1007/bf03401382 · Cited by 31
Hasenmajer, V., Sbardella, E., Sciarra, F., Simeoli, C., Pivonello, C., Ceccato, F., Pofi, R., Minnetti, M., Rizzo, F., Ferrari, D., et al. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2024.105462 · Cited by 29
Mondin, A., Ceccato, F., Voltan, G., Mazzeo, P., Manara, R., Denaro, L., Scaroni, C. M., & Barbot, M. (2023) · Pituitary · doi:10.1007/s11102-023-01343-2 · Cited by 31
“Hypercortisolism was suspected on the basis of the patient’s clinical features and it was confirmed by appropriate hormonal testing [low dose dexamethasone suppression test (LDDST), 24-h urinary free cortisol (UFC) and late-night salivary cortisol (LNSC)] after excluding the possibility of exogenous glucocorticoid int…”
BackgroundNanoarchitectonics of point-of-care diagnostics for sweat biomarkers analysis
Lin, X., Vasanth, A., Ashok, A., Phan, H., Koo, K. M., Amin, M. A., Kaneti, Y. V., Salomón, C., Hossain, M. S. A., Yamauchi, Y., et al. (2024) · Nano Materials Science · doi:10.1016/j.nanoms.2024.01.010 · Cited by 30
Medical management of Cushing’s disease
Tritos, N. A., & Biller, B. M. K. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1269-1 · Cited by 30
“The diagnosis and differential diagnosis of CD have been previously described and will not be discussed herein [2, 5].”
BackgroundSelf-citationJian, F., Chen, Y., Ning, G., Fu, W., Tang, H., Chen, X., Zhao, Y., Zheng, L., Pan, S., Wang, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7037 · Cited by 29
“It caused a series of complications, such as hypertension, obesity, dyslipidemia, diabetes mellitus, cardiovascular disease, osteoporosis, infections and psychiatric disorders, which associated with increased morbidity and mortality if not appropriately treated [3, 4].”
An Individualized Approach to the Evaluation of Cushing Syndrome
Sharma, S. T. (2017) · Endocrine Practice · doi:10.4158/ep161721.ra · Cited by 31
Pregnancy in Patients with Cushing’s Syndrome
Machado, M. C., Fragoso, M. C. B. V., & Bronstein, M. D. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.02.004 · Cited by 29
Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells
Asari, Y., Kageyama, K., Sugiyama, A., Kogawa, H., Niioka, K., & Daimon, M. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0491 · Cited by 28
“CUSHING’S DISEASE is a clinical syndrome in which hypercortisolemia results from excessive production of adrenocorticotropic hormone (ACTH) by pituitary corti‐ cotroph adenomas [1, 2].”
BackgroundLjubičić, M., Baković, L., Ćoza, M., Relja, A., & Kolčić, I. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104709 · Cited by 28
Endogenous cortisol excess confers a unique lipid signature and metabolic network
Vega‐Beyhart, A., Iruarrizaga‐Lejarreta, M., Pané, A., García-Eguren, G., Giró, O., Boswell, L., Aranda, G. B., Flores, V., Casals, G., Alonso, C., et al. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02076-0 · Cited by 33
“Diagnosis criteria of CS followed the Endocrine Society guidelines [10].”
MethodCyclic Cushing’s Syndrome – A Diagnostic Challenge
Świątkowska−Stodulska, R., Berlińska, A., Stefanska, K. A., Kłosowski, P., & Sworczak, K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.658429 · Cited by 31
Detomas, M., Ritzel, K., Nasi‐Kordhishti, I., Schernthaner-Reiter, M. H., Losa, M., Tröger, V., Altieri, B., Kroiß, M., Kickuth, R., Faßnacht, M., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad050 · Cited by 35
Cushing’s syndrome: an update on current pharmacotherapy and future directions
Creemers, S. G., Hofland, L. J., Lamberts, S. W. J., & Feelders, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1061995 · Cited by 31
“Most characteristic features of CS include central obesity, full, plethoric facial appearance, increased supraclavicular fat deposit, proximal muscle weakness and easy bruisability [1,10].”
BackgroundInfluentialRibeiro‐Oliveira, A., Abrantes, M. M., & Barkan, A. L. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1581 · Cited by 31
“These data show that GH rhythm in acromegaly is similar to that observed in normals, although possibly regulated at a higher hypothalamic set point, similarly to what has been described for glucocorticoid regulation in Cushing’s disease (8).”
ResultShort-term and Long-term Orthopaedic Issues in Patients With Fragility Fractures
Bukata, S. V., Kates, S. L., & O’Keefe, R. J. (2011) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-011-1779-0 · Cited by 29
“An overnight dexamethasone suppression test in which dexamethasone administration fails to suppress serum cortisol levels can aid in diagnosis [ 66 ].”
MethodPolycystic ovarian syndrome and Cushing's syndrome: a persistent diagnostic quandary
Brzana, J. A., Yedinak, C. G., Hameed, N., Plesiu, A., McCartney, S., & Fleseriu, M. (2014) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2013.12.038 · Cited by 31
Deutschbein, T., Unger, N., Hinrichs, J., Walz, M. K., Mann, K., & Petersenn, S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0517 · Cited by 28
Association Between Mifepristone Dose, Efficacy, and Tolerability in Patients With Cushing Syndrome
Yuen, K. C. J., Williams, G., Kushner, H., & Nguyen, D. (2015) · Endocrine Practice · doi:10.4158/ep15760.or · Cited by 28
“Cushing syndrome (CS) is a clinical state of prolonged exposure to inappropriately high levels of exogenous or endogenous glucocorticoids and is associated with significant morbidity and mortality (1-5).”
BackgroundMelmed, S. K., & Kleinberg, D. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00009-5 · Cited by 39
Mészáros, K., Karvaly, G., Márta, Z., Magda, B., Tőke, J., Szücs, N., Tóth, M., Rácz, K., & Patócs, A. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0743-6 · Cited by 27
Harrison, R. F., Debono, M., Whitaker, M. J., Keevil, B. G., Newell-Price, J., & Ross, R. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01172 · Cited by 27
“Urine requires 24-hour collection, which is often incomplete and in all studies shows reduced sensitivity and specificity for diagnosing cortisol excess compared with measurement of serum samples (17).”
BackgroundSelf-citationThe Endocrine System and the Heart: A Review
Rhee, S. S., & Pearce, E. N. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2010.10.016 · Cited by 46
Corticosteroid adulteration in proprietary Chinese medicines: a recurring problem
Hospital Authority Toxicology Reference Laboratory, P. M. H., Chong, Y., Ching, C., Ng, S., & Mak, T. W. (2015) · Hong Kong Medical Journal · doi:10.12809/hkmj154542 · Cited by 28
Ambrogio, A. G., Andrioli, M., De Martin, M., Cavagnini, F., & Pecori Giraldi, F. (2017) · Endocrine Connections · doi:10.1530/ec-17-0292 · Cited by 26
Endocrine causes of hypertension in pregnancy
Affinati, A. H., & Auchus, R. J. (2020) · Gland Surgery · doi:10.21037/gs.2019.12.04 · Cited by 28
“Unfortunately, gadolinium contrast must be avoided in the pregnant women, and the sensitivity of sella MRI for identifying CD tumors is therefore much lower (42,52).”
BackgroundHannah‐Shmouni, F., Berthon, A. S., Faucz, F. R., Briceno, J. M., Maria, A. G., Demidowich, A. P., Peitzsch, M., Masjkur, J. R., Bonnet-Serrano, F., Vaczlavik, A., et al. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0102 · Cited by 29
“Subjects were initially examined for clinical features of CS, and were considered positive if they had 2 or more of the following established screening tests for CS: elevated 24-hr urinary free cortisol above the upper cutoffs of reference intervals; elevated midnight salivary cortisol (>1·5 ng/mL), attesting the loss…”
MethodInfluentialFerrante, E., Barbot, M., Serban, A. L., Ceccato, F., Carosi, G., Lizzul, L., Sala, E., Daniele, A., Indirli, R., Cuman, M., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01695-1 · Cited by 28
FDG PET/CT Scan and Functional Adrenal Tumors: A Pilot Study for Lateralization
Patel, D., Gara, S. K., Ellis, R. J., Boufraqech, M., Nilubol, N., Millo, C., Stratakis, C. A., & Kebebew, E. (2015) · World Journal of Surgery · doi:10.1007/s00268-015-3242-y · Cited by 30
Ayala, A. R., & Manzano, A. J. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1508-0 · Cited by 32
“context of initial diagnosis of CD [10], there is no expert consensus with regard to post-operative testing for surgical success.”
BackgroundThe Hirsute Woman: Challenges in Evaluation and Management
Paparodis, R. D., & Dunaif, A. E. (2011) · Endocrine Practice · doi:10.4158/ep11117.ra · Cited by 27
Graham, U. M., Hunter, S. J., McDonnell, M., Mullan, K. R., & Atkinson, A. B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2925 · Cited by 27
“The Endocrine Society has also suggested the use of NSC to evaluate for cyclicity (5).”
MethodOwen, L. J., Haslam, S., Adaway, J. E., Wood, P., Glenn, C., & Keevil, B. G. (2010) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2009.009053 · Cited by 26
Aranda, G. B., Careaga, M., Hanzu, F. A., Patrascioiu, I., Ríos, P., Mora, M., Morales‐Romero, B., Jiménez, W., Halperín, I., & Casals, G. (2016) · Pituitary · doi:10.1007/s11102-016-0730-5 · Cited by 34
“In our study, reference values were obtained in the same group of healthy controls by both immunoassay and mass spectrometry, generating comparable cut points based on UFC levels above the standard range recommended in the Endocrine Society Clinical Practice Guideline [3].”
BackgroundMethodInfluentialMete, Ö., & Duan, K. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00054 · Cited by 29
Diagnosis and management of pituitary adenomas
Lleva, R. R., & Inzucchi, S. E. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328341000f · Cited by 27
Ramm‐Pettersen, J., Halvorsen, H. L., Evang, J. A., Rønning, P. A., Hol, P. K., Bollerslev, J., Berg–Johnsen, J., & Helseth, E. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0055-9 · Cited by 28
“Once the diagnosis of ACTH-dependent Cushing’s syndrome was established [17], a multidisciplinary team, consisting of an endocrinologist, radiologist, oncologist and neurosurgeon, discussed the patients and established the indication for surgery.”
BackgroundWitek, P., Zieliński, G., Szamotulska, K., Maksymowicz, M., & Kamiński, G. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1226 · Cited by 26
Hawley, J. M., Owen, L. J., Debono, M., Newell-Price, J. D. C., & Keevil, B. G. (2018) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563218766566 · Cited by 28
Self-citationPituitary-Directed Therapies for Cushing’s Disease
Langlois, F., Chu, J. M., & Fleseriu, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00164 · Cited by 28
Pituitary Disorders in Pregnancy
Woodmansee, W. W. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.09.009 · Cited by 33
Serum steroid profiling in Cushing’s syndrome patients
Hána, V., Ježková, J., Kosák, M., Kršek, M., Hána, V., & Hill, M. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105410 · Cited by 27
The Hypothalamic-Pituitary-Thyroid Axis in Cushing Syndrome Before and After Curative Surgery
Shekhar, S., McGlotten, R., Auh, S., Rother, K. I., & Nieman, L. K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa858 · Cited by 26
Self-citationA multidisciplinary approach to the management of adrenal incidentaloma
Voltan, G., Boscaro, M., Armanini, D., Scaroni, C. M., & Ceccato, F. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1948327 · Cited by 30
“<50 nmol/L after 1-mg DST (the same indicated in the Guidelines of overt Cushing’s syndrome [39]).”
BackgroundA New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score
Parasiliti‐Caprino, M., Bioletto, F., Frigerio, T., D’Angelo, V., Ceccato, F., Ferraù, F., Ferrigno, R., Minnetti, M., Scaroni, C. M., Cannavò, S., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.747549 · Cited by 29
“The Endocrine Society (ES) guidelines for CS recommend the initial use of at least one of the following tests: 24-hour urinary free cortisol (UFC), late-night salivary cortisol (LNS-F), 1 mg overnight or 2 mg 48-hour dexamethasone suppression test (DST) (15).”
MethodInfluentialThe effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study
Sada, A., Foster, T. R., Al-Ward, R., Sawani, S., Charchar, H. L. S., Pishdad, R., Ben-Shlomo, A., Dy, B. M., Lyden, M. L., Bergsland, E. K., et al. (2023) · Surgery · doi:10.1016/j.surg.2023.04.070 · Cited by 28
Diagnosis and treatment of pediatric Cushing’s disease
Savage, M. O., Storr, H. L., Chan, L. F., & Grossman, A. B. (2007) · Pituitary · doi:10.1007/s11102-007-0056-4 · Cited by 26
“Consistent with current recommendations [20], our initial screening test includes three consecutive 24-h urine collections for urinary free cortisol (UFC).”
BackgroundMethodInfluentialSelf-citationLee, S.-H., Kwon, S.-H., Shin, H.-J., Lim, H.-S., Singh, R. J., Lee, K.-R., & Kim, Y.-J. (2010) · BMB Reports · doi:10.3858/bmbrep.2010.43.7.506 · Cited by 26
Current status and controversies in adrenal incidentalomas
Kaltsas, G., Chrisoulidou, A., Piaditis, G. P., Kassi, E. N., & Chrousos, G. P. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.09.001 · Cited by 27
Diagnosis and Multimodality Management of Cushing’s Disease: A Practical Review
Zada, G. (2013) · International Journal of Endocrinology · doi:10.1155/2013/893781 · Cited by 27
“Establishing an accurate diagnosis of Cushing’s Disease relies on a thorough and stepwise sequence of laboratory and imaging studies (Figure 1) [16].”
MethodGNAS mutations in adrenal aldosterone-producing adenomas [Rapid Communication]
Nakajima, Y., Okamura, T., Horiguchi, K., Gohko, T., Miyamoto, T., Satoh, T., Ozawa, A., Ishii, S., Yamada, E., Hashimoto, K., et al. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej15-0642 · Cited by 29
“Funder J, Carey R, Fardella C, Gomez-Sanchez CE, Mantero F, et al. (2008) Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.”
MethodInfluentialDe Sousa, S. M. C., McCormack, A. I., McGrath, S., & Torpy, D. J. (2017) · Clinical Endocrinology · doi:10.1111/cen.13401 · Cited by 26
Mamoojee, Y. H., Ganguri, M., Taylor, N., & Quinton, R. (2017) · Clinical Endocrinology · doi:10.1111/cen.13492 · Cited by 28
Genetics of micronodular adrenal hyperplasia and Carney complex
Tirosh, A., Valdés, N., & Stratakis, C. A. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.07.005 · Cited by 29
“suppressed or low ACTH suggests primary adrenal CS, whereas levels above 30 pg/mL suggest ACTH-dependent disease [11].”
BackgroundInfluentialAccuracy of microcystic aspect on T2‐weighted MRI for the diagnosis of silent corticotroph adenomas
Kasuki, L., Antunes, X. L. D. S., Coelho, M. C. A., Lamback, E. B., Galvão, S., Camacho, A. H. S., Chimelli, L. M. C., Ventura, N., & Gadelha, M. R. (2019) · Clinical Endocrinology · doi:10.1111/cen.14133 · Cited by 27
Glucocorticoids are active players and therapeutic targets in atherosclerotic cardiovascular disease
van der Sluis, R. J., & Hoekstra, M. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110728 · Cited by 27
“In children, Cushing's syndrome can also be apparent from excessive weight gain (obesity) in the context of decreasing growth velocity (Nieman et al., 2008).”
Reimondo, G., Bovio, S., Allasino, B., De Francia, S., Zaggia, B., Micossi, I., Termine, A., De Martino, F., Paccotti, P., Di Carlo, F., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0402 · Cited by 26
Chiodini, I., Ramos-Rivera, A., Marcus, A. O., & Yau, H. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2018-00382 · Cited by 25
“Patients with newly discovered adrenal adenomas and/or signs and symptoms leading to a suspicion of hypercortisolism should undergo biochemical screening [11].”
BackgroundMethodInfluentialPonzetto, F., Settanni, F., Parasiliti-Caprino, M., Rumbolo, F., Nonnato, A., Ricciardo, M., Amante, E., Priolo, G., Vitali, S., Anfossi, L., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01388-1 · Cited by 25
Endogenous Cushing’s syndrome during pregnancy
Younès, N., St‐Jean, M., Bourdeau, I., & Lacroix, A. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09731-y · Cited by 29
Cushing Syndrome Is Associated With Gut Microbial Dysbiosis and Cortisol-Degrading Bacteria
Zhang, M., Shi, Z., Wu, C., Yang, F., Su, T., Jing, X., Shi, J., Ren, H., Jiang, L., Jiang, Y., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad766 · Cited by 30
Hypothalamic-pituitary-adrenal axis in lethal canine Staphylococcus aureus pneumonia
Cortés‐Puch, I., Hicks, C. W., Sun, J., Solomon, S. B., Eichacker, P. Q., Sweeney, D. A., Nieman, L. K., Whitley, E. M., Behrend, E. N., Natanson, C., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00345.2014 · Cited by 27
“Also, unlike Cushing’s syndrome (45) and perhaps due to intact negative feedback, the ACTH response to CRH stimulation testing is blunted in functional hypercortisolism.”
BackgroundSelf-citationAmbrogio, A. G., Martin, M. D., Ascoli, P., Cavagnini, F., & Giraldi, F. P. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0824 · Cited by 29
Kubota-Nakayama, F., Nakamura, Y., Konosu‐Fukaya, S., Azmahani, A., Ise, K., Yamazaki, Y., Kitawaki, Y., Felizola, S. J. A., Ono, Y., Omata, K., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.03.016 · Cited by 27
The definition of remission and recurrence of Cushing’s disease
Hinojosa‐Amaya, J. M., & Ramos, D. C. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101485 · Cited by 28
Hypercoagulability in Cushing’s syndrome: From arterial to venous disease
St‐Jean, M., Lim, D. S. T., & Langlois, F. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101496 · Cited by 25
Medullary thyroid cancer with ectopic Cushing's syndrome: A multicentre case series
Koehler, V. F., Fuß, C. T., Berr, C., et al. (2021) · Clinical Endocrinology · doi:10.1111/cen.14617 · Cited by 25
Subtype-specific pattern of white blood cell differential in endogenous hypercortisolism
Detomas, M., Altieri, B., Chifu, I. O., Remde, H., Zhou, X., Landwehr, L., Sbiera, S., Kroiß, M., Faßnacht, M., & Deutschbein, T. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0211 · Cited by 27
Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Belaya, Z. E., Danilov, N. M., Elfimova, E. M., Litvin, A. Y., Rozhinskaya, L. Y., Sviridenko, N. Y., Швецов, М. Ю., et al. (2023) · Eurasian heart journal · doi:10.38109/2225-1685-2023-1-6-65 · Cited by 35
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.